1346233-68-8
1346233-68-8 性质
| 沸点 | 455.5±35.0 °C(Predicted) |
|---|---|
| 密度 | 1.184±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO：可溶10mg/mL（澄清溶液） |
| 酸度系数(pKa) | 13.65±0.46(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至米色 |
1346233-68-8 用途与合成方法
IC50: 310 nM (Cav3.2), 270 nM (Cav3.3), and 150 nM (Ca 2+ flux)
In plasma protein binding studies (equilibrium dialysis), ML218 possesses good free fraction in both rat and human. Intrinsic clearance experiments in liver microsomes indicated that ML218 is highly cleared in rat (CL int = 115 mL/min/kg), but low to moderately cleared in human liver microsomes (CL int = 12.7 mL/min/kg).
ML218 (0.03-30 mg/kg; oral administration; once; male Sprague-Dawley rats) treatment reverses cataleptic behavior in rats induced by a 0.75 mg/kg dose of haloperidol.
Free brain and plasma concentrations of ML218 increases in a dose proportional manner across the dose range (3 mg/kg: [plasma] = 98 nM, [brain] = 1.66 μM; 10 mg/kg: [plasma] = 282 nM, [brain] = 5.03 μM; 30 mg/kg: 1.2 μM, [brain] = 17.7 μM).
Noncompartmental pharmacokinetic analysis indicates ML218 (1 mg/kg, IV) has a mean residence time (MRT) of nearly 7 h, a value which is consistent with its terminal half-life (t
1/2
= 7 h).
| Animal Model: | Male Sprague-Dawley rats (275-299 g) induced by haloperidol |
| Dosage: | 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg |
| Administration: | Oral administration; once |
| Result: | Reversed cataleptic behavior in rats induced by a 0.75 mg/kg dose of haloperidol. |
1346233-68-8 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-04-30 | HY-103309 | 1 mg | 818 | ||
| 2024-04-30 | HY-103309 | 1346233-68-8 | 1346233-68-8 | 5mg | 1800 |
